Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 37289220)

  • 1. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
    Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
    Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
    Sasagawa Y; Akai T; Tachibana O; Iizuka H
    J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
    BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
    Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
    J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
    Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
    Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry.
    Krogh-Jensen M; D'Amore F; Jensen MK; Christensen BE; Thorling K; Pedersen M; Johansen P; Boesen AM; Andersen E
    Leuk Lymphoma; 1995 Oct; 19(3-4):223-33. PubMed ID: 8535213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
    Whitcup SM; Stark-Vancs V; Wittes RE; Solomon D; Podgor MJ; Nussenblatt RB; Chan CC
    Arch Ophthalmol; 1997 Sep; 115(9):1157-60. PubMed ID: 9298057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
    Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
    [No Abstract]   [Full Text] [Related]  

  • 13. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
    Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
    Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
    Mizowaki T; Sasayama T; Tanaka K; Mizukawa K; Takata K; Nakamizo S; Tanaka H; Nagashima H; Nishihara M; Hirose T; Itoh T; Kohmura E
    J Neurooncol; 2015 Sep; 124(2):165-74. PubMed ID: 26080800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
    De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
    Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 18. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
    Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
    Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
    Jang JE; Kim YR; Kim SJ; Cho H; Chung H; Lee JY; Park H; Kim Y; Cheong JW; Min YH; Kim JS
    Eur J Cancer; 2016 Apr; 57():127-35. PubMed ID: 26918738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome and prognostic factors in PCNSL.
    Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
    Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.